Chronic obstructive pulmonary disease (COPD) is a progressive, debilitating respiratory disease that represents a massive therapeutic and economic burden for healthcare systems worldwide. Characterized by persistent respiratory symptoms and airflow limitation, COPD is primarily driven by long-term exposure to noxious particles or gases, most commonly tobacco smoke. For more than twenty years, the pharmacological management of chronic stable COPD was dominated by inhaled bronchodilators and inhaled corticosteroid (ICS) combinations. While these therapies are highly effective at managing daily symptoms and reducing exacerbation frequency, they do not halt the underlying disease progression or address the heterogeneous inflammatory pathways present in severe phenotypes.
Recently, the regulatory and commercial landscapes for COPD have undergone a major transformation. The introduction of first-in-class biologics and novel inhaled mechanisms has broken this two-decade innovation drought. These new options allow clinical respiratory teams to implement targeted therapies for patients with severe disease, particularly those exhibiting type 2 or eosinophilic airway inflammation. However, the introduction of high-cost specialty therapies into a highly populated disease state creates significant financial exposure for commercial plans and Medicare sponsors.
This respiratory access landscape reviews the clinical, operational, and financial realities of managing COPD therapies in 2026. We examine the foundational long-acting inhaled therapy base, the clinical trial evidence and indication boundaries for dupilumab (Dupixent), the nebulized specialty distribution of the dual PDE3/4 inhibitor ensifentrine (Ohtuvayre), the comparison between inhaled and oral PDE4 inhibitors, the May 2025 FDA approval of mepolizumab (Nucala), and the prior authorization (PA) and utilization management (UM) frameworks that payers apply to manage respiratory specialty spend.
Executive Summary & Scenario Analysis
To align on the pricing and access dynamics for chronic obstructive pulmonary disease (COPD) therapies, we must address the primary questions facing clinical pharmacy directors and benefit designers.
Scenario Question
Which COPD drugs are accessible and affordable in 2026, and how do dupilumab and ensifentrine fit on top of the inhaled-triple-therapy base under GOLD 2025?
Direct Answer
COPD maintenance therapy begins with long-acting inhaled bronchodilators (LAMA/LABA) and single-inhaler triple therapy (LAMA/LABA/ICS) per the GOLD 2025 report, with most components available as cheap generics in the CMS NADAC registry (e.g., generic fluticasone-vilanterol is $3.88 per dose compared to Trelegy Ellipta brand at $11.15 per dose). On top of this inhaled base, two first-in-class mechanisms broke a 20-year innovation drought: ensifentrine (Ohtuvayre, NDA 217389), a dual PDE3/4 inhibitor suspension dosed twice daily via standard jet nebulizer (approved June 26, 2024 based on ENHANCE-1/ENHANCE-2), and dupilumab (Dupixent, BLA 761055 supplement), the first biologic for COPD, approved September 27, 2024 as add-on maintenance for inadequately controlled COPD with an eosinophilic phenotype (blood eosinophils at least 300/microL based on BOREAS and NOTUS). A third biologic, mepolizumab (Nucala), was approved on May 22, 2025 for inadequately controlled COPD with blood eosinophils at least 150/microL (MATINEE/METREX). In the CMS NADAC snapshot, Dupixent is priced at $1,008.40 per mL (for the 300 mg/2 mL pen), while Ohtuvayre is a nebulized specialty product excluded from the retail-pharmacy NADAC registry, requiring distribution through specialty durable medical equipment (DME) channels.
The Foundational Inhaled Base: LAMA/LABA and Triple Therapy
The global standard for diagnosing and managing COPD is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines. The GOLD 2025 report structures pharmacotherapy using the ABE assessment tool, which evaluates patients based on symptom burden (mMRC scale or COPD Assessment Test [CAT] score) and their history of moderate-to-severe exacerbations.
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| GOLD 2025 INHALED MAINTENANCE ALGORITHM |
+------------------------------------+------------------------------------+------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+
| Patient Group | Clinical Characteristics | Preferred Initial Therapy | Pricing & Access Status (CMS NADAC) |
+------------------------------------+------------------------------------+------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+
| Group A | Low symptoms (CAT < 10), | Single long-acting bronchodilator | Low cost. Generics like generic glycopyrrolate ($0.11–$0.23/unit) are widely available on Tier 1. |
| | 0–1 moderate exacerbations | (LAMA or LABA) | |
+------------------------------------+------------------------------------+------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+
| Group B | High symptoms (CAT >= 10), | Dual bronchodilation | Moderate cost. Brand combinations like Anoro Ellipta ($7.81/EA) or generic alternatives (umeclidinium-vilanterol $4.97/EA) are used. |
| | 0–1 moderate exacerbations | (LAMA + LABA) | |
+------------------------------------+------------------------------------+------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+
| Group E | High symptoms, | Dual bronchodilation (LAMA+LABA) | LAMA+LABA/ICS preferred if blood eosinophils >= 300 cells/µL. Single-inhaler triple therapy (Trelegy $11.15/EA; generic fluticasone-vilanterol |
| | >= 2 moderate or 1 severe | or Triple therapy (LAMA+LABA+ICS) | $3.88/EA) provides high compliance. |
| | hospitalization | | |
+------------------------------------+------------------------------------+------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------+
Inhaled Dual Bronchodilation (LAMA + LABA)
For symptomatic patients (Group B and E), clinical guidelines recommend dual long-acting bronchodilation combining a Long-Acting Muscarinic Antagonist (LAMA) with a Long-Acting Beta2-Agonist (LABA). This combination targets distinct G-protein coupled receptor pathways in airway smooth muscle: LAMAs block M3 muscarinic receptors to inhibit vagal-mediated bronchoconstriction, while LABAs stimulate beta2-adrenergic receptors to increase intracellular cAMP, promoting smooth muscle relaxation. In the CMS NADAC snapshot:
- Brand Anoro Ellipta (umeclidinium/vilanterol) is priced at $7.81296 per inhaler dose (Classification for Rate Setting = B).
- Generic umeclidinium-vilanterol Ellipta is priced at $4.97444 per dose (Classification = G), representing a 36% discount on the wholesale acquisition index.
Single-Inhaler Triple Therapy (LAMA + LABA + ICS)
For patients in Group E who continue to experience frequent exacerbations despite dual bronchodilation and exhibit blood eosinophil counts of 300 cells/µL or greater, the guidelines recommend escalating to triple therapy. This regimen adds an Inhaled Corticosteroid (ICS) to the LAMA/LABA backbone to target eosinophilic airway inflammation. In the CMS NADAC snapshot:
- Brand Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is priced at $11.15025 per dose (100-62.5-25 mcg strength) and $11.16264 per dose (200-62.5-25 mcg strength).
- Generic fluticasone-vilanterol Ellipta (100-25 mcg strength) is available at $3.87597 per dose (Classification = G).
Payers actively manage these products to ensure adherence. Encouraging the use of single-inhaler triple therapy instead of separate, multi-device fills reduces copay friction and enhances clinical outcomes. For background on inhaled device delivery and Orange Book patent listings, see the single-source inhaled products analysis.
Dupilumab: The First Biologic for Eosinophilic COPD
Despite receiving triple inhaled therapy, a subset of severe COPD patients continues to experience recurrent, life-threatening exacerbations. On September 27, 2024, the FDA approved dupilumab (Dupixent, BLA 761055) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. This approval represented the first biologic option indicated for COPD, targeting type 2 pathway inflammation.
Clinical Trial Foundations: BOREAS and NOTUS
The efficacy and safety of dupilumab in COPD were evaluated in two pivotal, double-blind, randomized Phase III trials: BOREAS (NCT03930732) and NOTUS (NCT04456673). Both trials enrolled symptomatic COPD patients on triple inhaled therapy who had a blood eosinophil count of 300 cells/µL or greater and a history of at least two moderate or one severe exacerbation in the prior year.
- Annualized Exacerbation Rate: In the BOREAS trial, dupilumab (300 mg subcutaneously every two weeks) demonstrated a 30% reduction in the rate of moderate or severe COPD exacerbations compared to placebo ($p < 0.001$). In the NOTUS trial, dupilumab demonstrated a 34% reduction in annualized exacerbations ($p < 0.001$).
- Lung Function Improvement: Dupilumab showed significant improvements in pre-bronchodilator FEV1. In the BOREAS trial, the improvement at week 12 was 160 mL in the dupilumab group compared to 77 mL in the placebo group ($p < 0.001$), with the benefit sustained at week 52 (least-squares mean difference of about 83 mL). In NOTUS, the week-12 FEV1 increase was 139 mL vs. 57 mL ($p < 0.001$), sustained at about 62 mL at week 52.
- Quality of Life: Both studies reported improvements in quality-of-life scores, measured by the St. George's Respiratory Questionnaire (SGRQ), and reductions in symptom severity.
Payer Prior Authorization Criteria for Dupixent
In the CMS NADAC snapshot, Dupixent remains a high-cost specialty drug, priced at $1,008.40702 per mL for the 300 mg/2 mL pen/syringe (translating to approximately $2,016.81 per biweekly dose or over $52,000 annually). The 200 mg/1.14 mL strength is priced at $1,772.99139 per mL.
To manage this high specialty spend, payers implement strict prior authorization criteria:
- Guideline-Recommended Base: Documentation that the patient is adherent to a stable, optimized regimen of triple inhaled therapy (LAMA + LABA + ICS) for at least 3 consecutive months.
- Exacerbation History: Documented history of at least two moderate exacerbations requiring systemic corticosteroids or antibiotics, OR at least one severe exacerbation requiring hospitalization, within the past 12 months while on triple therapy.
- Eosinophilic Phenotype: A documented blood eosinophil count of at least 300 cells/µL within the past 12 months, measured before initiating dupilumab.
- Clinical Exclusions: Exclusion of patients with active diagnoses of asthma (which are managed under separate criteria) or other pulmonary conditions like idiopathic pulmonary fibrosis. For more details on dupilumab's access criteria across other type-2 indications, see the Dupixent coverage guide and the severe-asthma biologic access landscape.
Ensifentrine: A Novel Nebulized Dual PDE3/4 Mechanism
On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre, NDA 217389) as an add-on maintenance treatment for adult patients with COPD. Ensifentrine represents the first inhaled novel-mechanism therapy approved for COPD maintenance in more than twenty years. It functions as a dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes, combining bronchodilator activity (via PDE3 inhibition in airway smooth muscle) with non-steroidal anti-inflammatory effects (via PDE4 inhibition in inflammatory cells).
Clinical Trial Foundations: ENHANCE-1 and ENHANCE-2
The safety and efficacy of ensifentrine were demonstrated in two randomized, double-blind Phase III trials: ENHANCE-1 (NCT04559191) and ENHANCE-2 (NCT04568291). These trials evaluated ensifentrine (3 mg twice daily) administered via a standard jet nebulizer compared to placebo, both as monotherapy and in combination with background LAMA or LABA therapy.
- Lung Function Improvement: In ENHANCE-1, ensifentrine demonstrated a statistically significant placebo-adjusted increase in average FEV1 AUC0-12 of 87 mL at week 12 ($p < 0.001$). In ENHANCE-2, the placebo-adjusted improvement was 94 mL ($p < 0.001$).
- Exacerbation Rate Reduction: In both trials, ensifentrine significantly reduced the risk of moderate or severe COPD exacerbations. Over 24 weeks, ensifentrine demonstrated a 36% reduction in exacerbation risk in ENHANCE-1 ($p = 0.001$) and a 43% reduction in ENHANCE-2 ($p = 0.009$).
- Safety Profile: Ensifentrine was well-tolerated. Unlike oral PDE4 inhibitors, which cause significant gastrointestinal adverse events (diarrhea, nausea, weight loss) due to systemic PDE4D inhibition, ensifentrine's inhaled delivery directly targets the lungs, maintaining gastrointestinal adverse event rates comparable to placebo.
Specialty DME Channel Distribution & NADAC Exclusion
A key operational distinction for ensifentrine is its distribution. Dosed as a 3 mg/2.5 mL unit-dose inhalation suspension twice daily, Ohtuvayre is distributed as a nebulized specialty drug. It returns 0 rows in the CMS NADAC registry, indicating that it is excluded from the retail-pharmacy acquisition-cost dataset.
INHALED COMBOS VS. NEBULIZED SPECIALTY FLOW
[Standard Retail Pharmacy] [Specialty DME Channel]
- Trelegy Ellipta (ICS/LAMA/LABA) - Ohtuvayre (Ensifentrine)
- Generic Fluticasone-Vilanterol - Nebulized specialty suspension
- Dosed via dry powder/metered dose - Dosed via standard jet nebulizer
- Flow: Pharmacy Benefit - Flow: Durable Medical Equipment (DME)
- Cost tracked in CMS NADAC - Cost excluded from CMS NADAC
Because Ohtuvayre is a nebulized specialty product, patient access flows through specialized durable medical equipment (DME) channels rather than standard retail pharmacy fills. Payer benefit designs manage Ohtuvayre under the medical benefit (as a DME supply) or the specialty pharmacy benefit, requiring coordination with specific specialty pharmacies that support jet nebulizer setup and compliance. For a clinical and methodology overview of the NADAC dataset, see the CMS NADAC by-the-numbers analysis.
Inhaled vs. Oral PDE4 Inhibition: Ohtuvayre vs. Roflumilast (Daliresp)
To understand Ohtuvayre's clinical positioning and payer tiering, we must compare it with the established oral PDE4 inhibitor, roflumilast (Daliresp, approved in 2011).
+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| PDE4 INHIBITOR COMPARATIVE SPECIFICATION |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Feature/Metric | Oral Roflumilast | Inhaled Ensifentrine (Ohtuvayre) | Payer & Clinical Significance |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 1. Route of Administration | Oral Tablet (500 mcg QD)| Nebulized Suspension (3 mg BID) | Oral offers convenience; nebulized bypasses poor inhaler technique and is preferred for patients with severe mechanical limitation. |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 2. Isoform Selectivity | Non-selective PDE4 | Dual PDE3 / PDE4 (preferential B) | PDE3 inhibition provides direct bronchodilation; PDE4B selectivity reduces system-wide toxicities. |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 3. Gastrointestinal Adverse Events | High (10-15% diarrhea, | Low (Comparable to placebo; | High discontinuation rate of oral roflumilast due to nausea/weight loss. Inhaled Ohtuvayre avoids systemic GI clearance. |
| | weight loss, nausea) | diarrhea ~1.5-2.0%) | |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
| 4. Pricing & Access Status | Generic (Low Cost) | Brand Only (Specialty DME) | Payers require trial and failure of generic oral roflumilast before authorizing coverage for high-cost Ohtuvayre. |
+------------------------------------+-------------------------+------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------+
Roflumilast carries a Class 2b recommendation in the GOLD guidelines, specifically for patients with chronic bronchitis, severe airflow limitation (FEV1 < 50%), and a history of frequent exacerbations. However, its real-world use is restricted by its poor tolerability profile. Clinical studies show that up to 15-20% of patients discontinue oral roflumilast within the first 3 months due to severe diarrhea, vomiting, and unintended weight loss.
Ohtuvayre's dual PDE3/4 inhaled delivery provides a significant clinical advantage. By inhibiting PDE3, Ohtuvayre induces immediate bronchodilation that is additive to LAMA/LABA baseline therapies, while the PDE4 inhibition addresses chronic airway inflammation. Because the drug is cleared locally and does not result in high systemic levels, the GI side effects that limit oral roflumilast are avoided. Nonetheless, because generic oral roflumilast is highly inexpensive, payers typically require documentation of intolerance or therapeutic failure on oral roflumilast before approving coverage for brand-only Ohtuvayre.
Mepolizumab: The May 2025 Eosinophilic COPD Approval
The biologic layer for COPD expanded further on May 22, 2025, when the FDA approved mepolizumab (Nucala, BLA 125526 supplement) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. Mepolizumab is a humanized monoclonal antibody that targets interleukin-5 (IL-5), blocking its binding to the IL-5 receptor on eosinophils and thereby reducing eosinophil survival and activity.
Clinical Trial Foundations: MATINEE and METREX
The FDA approval of mepolizumab was supported by the Phase III MATINEE and METREX trials (with METREO as an earlier exploratory dose-ranging study in the same program).
- METREX Trial (NCT02105948): Evaluated mepolizumab 100 mg subcutaneously every 4 weeks in patients with a history of exacerbations and blood eosinophil counts of at least 150 cells/µL at screening or 300 cells/µL in the prior year. Mepolizumab demonstrated an 18% reduction in the rate of moderate-to-severe exacerbations compared to placebo (rate ratio 0.82, 95% CI 0.68–0.98, p = 0.04).
- METREO Trial (NCT02105961): An exploratory dose-ranging study evaluating mepolizumab 100 mg and 300 mg doses. The efficacy variance seen here contributed to the FDA's request for additional confirmatory evidence.
- MATINEE Trial (NCT04133909): This confirmatory trial evaluated mepolizumab 100 mg every 4 weeks in COPD patients with an eosinophilic phenotype (blood eosinophils ≥ 300 cells/µL at screening) on triple inhaled therapy. MATINEE met its primary endpoint, demonstrating a statistically significant 21% reduction in the annualized rate of moderate-to-severe exacerbations over 52 weeks compared to placebo (rate ratio 0.79, 95% CI 0.66–0.94), providing the confirmatory evidence required for approval. The FDA label carries the broadest eligibility tested across the program, allowing use at blood eosinophils ≥ 150 cells/µL.
Payer Comparison: Nucala vs. Dupixent in COPD
With the approval of mepolizumab, payers must establish clinical differentiation criteria:
- Eosinophil Thresholds: Mepolizumab's label allows initiation in patients with blood eosinophil counts of at least 150 cells/µL, whereas dupilumab's label is restricted to patients with counts of at least 300 cells/µL. Mepolizumab thus offers an option for patients with moderate eosinophilic inflammation who fail triple therapy.
- Dosing Frequency: Mepolizumab is administered once every 4 weeks, compared to dupilumab's once every 2 weeks dosing, potentially offering a compliance advantage for patients.
- Payer Step-Edits: Payers typically place both Nucala and Dupixent on the preferred specialty tier, requiring a documented trial and failure of triple inhaled therapy and enforcing the respective eosinophil thresholds before authorizing coverage.
Clinical Trial Patient Profiles and Demographics: BOREAS, NOTUS, and MATINEE
To evaluate how these new biologics fit within clinical practice, it is helpful to examine the baseline patient profiles enrolled in their registrational trials. These demographics and clinical parameters illustrate the high disease severity of the target populations and help payers align prior authorization criteria with trial-validated clinical cohorts.
In the BOREAS and NOTUS trials for dupilumab:
- Age and Smoking Status: The average age of enrolled patients was approximately 65 years. All patients had a history of significant smoking, with a mean exposure of over 40 pack-years. Current smokers represented approximately 30% of the cohort, while former smokers accounted for 70%.
- Lung Function Baseline: The baseline pre-bronchodilator FEV1 was approximately 1.1 liters, representing about 38% of predicted normal values. This indicates severe airflow limitation before biologic initiation.
- Exacerbation Rate History: Patients had an average of 2.3 moderate-to-severe exacerbations in the 12 months prior to screening despite receiving baseline triple inhaled therapy, demonstrating a high-risk phenotype.
- Biomarkers: The median blood eosinophil count was approximately 360 cells/µL, and baseline fraction of exhaled nitric oxide (FeNO) was elevated, highlighting the type 2 inflammatory phenotype.
In the MATINEE trial for mepolizumab:
- Cohort Characteristics: Eosinophil thresholds were lower (at least 150 cells/µL at screening or 300 cells/µL in the prior year). The average baseline blood eosinophil count was approximately 270 cells/µL.
- Severity Markers: Enrolled patients exhibited a baseline FEV1 of approximately 42% of predicted values, and all patients had chronic bronchitis as their primary clinical presentation.
- Exacerbation History: Similar to the dupilumab trials, the cohort had a mean of 2.2 moderate-to-severe exacerbations in the preceding year while on daily triple maintenance therapy.
Payers use these detailed profiles to verify that biologic coverage is reserved for patients who match the trial parameters, preventing off-label use in patients with low-severity disease or non-eosinophilic phenotypes.
Operational and Supply Chain Tensions in Specialty Nebulizer Delivery
The approval of ensifentrine (Ohtuvayre) as a nebulized suspension introduces operational complexities distinct from standard retail dry-powder or metered-dose inhalers. Payer clinical operations teams must address these distribution differences to prevent delays in therapy initiation.
- Benefit Routing Matrix: While standard inhalers are adjudicated in real-time under the pharmacy benefit (using NDC codes at retail pharmacies), Ohtuvayre is often routed through the Medical Benefit as Durable Medical Equipment (DME). This requires submitting HCPCS codes (such as J-codes or temporary Q-codes) along with documentation of the patient's nebulizer equipment lease or purchase.
- The Jet Nebulizer Requirement: The Ohtuvayre label specifies administration via a standard jet nebulizer connected to an air compressor. High-efficiency mesh nebulizers or ultrasonic devices have not been validated for ensifentrine delivery, as they may alter the drug suspension's droplet size distribution. Specialty pharmacies must verify that the patient possesses an compatible jet nebulizer before shipping the drug.
- Limited Distribution Networks: Ohtuvayre's developer, Verona Pharma, distributes the drug through a restricted network of specialty pharmacies. These pharmacies provide patient training, verify nebulizer compatibility, and manage clinical adherence, but the closed network can increase administrative friction for prescribing clinics.
Payers should establish clear electronic prior authorization (ePA) templates that address these operational steps, ensuring that patients receive nebulizer supplies alongside their medication shipments to maintain clinical compliance.
COPD Class Affordability & Pricing Benchmarks
To assist pharmacy directors in constructing formulary tiers, the table below consolidates the retail pharmacy acquisition cost benchmarks for the COPD class, compiled from the CMS NADAC snapshot.
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| COPD PRICING BENCHMARKS (CMS NADAC SNAPSHOT) |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Drug Name | Brand/Generic | NDC Code | NADAC Per Unit | Pricing Unit | Monthly Cost (30-Day Supply)* |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Trelegy Ellipta 100-62.5-25 mcg | Brand | 00173-0887-10 | $11.15025 | EA (Inhalation Dose) | $334.51 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Trelegy Ellipta 200-62.5-25 mcg | Brand | 00173-0891-10 | $11.16264 | EA (Inhalation Dose) | $334.88 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Anoro Ellipta 62.5-25 mcg | Brand | 00173-0869-10 | $7.81296 | EA (Inhalation Dose) | $234.39 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Umeclidinium-Vilanterol | Generic | 00173-0932-10 | $4.97444 | EA (Inhalation Dose) | $149.23 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Fluticasone-Vilanterol 100 | Generic | 00173-0941-10 | $3.87597 | EA (Inhalation Dose) | $116.28 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Tiotropium 18 mcg | Generic | 00054-0196-18 | $11.95456 | EA (Inhaler Capsule) | $358.64 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Dupixent 300 mg/2 mL | Brand | 00024-5914-01 | $1,008.40702 | ML (Subcutaneous Injection) | $4,033.63 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Dupixent 200 mg/1.14 mL | Brand | 00024-5918-01 | $1,772.99139 | ML (Subcutaneous Injection) | $4,042.42 |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Ohtuvayre 3 mg/2.5 mL | Brand (Specialty Only) | 73238-0003-01 | $0.00000 | Excluded (Nebulized Specialty) | Specialty DME/Hub Channel |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
| Generic Glycopyrrolate 1 mg | Generic | 00054-0231-25 | $0.11038 | EA (Tablet) | $6.62 (BID dosing) |
+------------------------------------+-------------------------+------------------------+---------------------+-----------------------------------+-------------------------------------+
*Note: Monthly cost calculations assume standard daily dosing (30 inhalation doses/month) for Trelegy, Anoro, umeclidinium-vilanterol, fluticasone-vilanterol, and tiotropium; and biweekly dosing (4 mL/month) for Dupixent. Glycopyrrolate tablets assume twice-daily dosing.
Payers should leverage these pricing benchmarks to enforce cost-effective inhaled therapy step-edits before authorizing high-cost biologics. Transitioning patients to generic inhaled combos (e.g. fluticasone-vilanterol) captures over 60% savings compared to brand-name alternatives, establishing a solid baseline before specialty biologic spend is opened.
FAQ Section
Is dupilumab (Dupixent) covered for COPD, and what eosinophil count is required?
Yes, dupilumab (Dupixent) is covered by most commercial insurance and Medicare Part D plans as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. To qualify for coverage, payers require documentation of a blood eosinophil count of at least 300 cells/µL measured within the past 12 months, along with a documented history of frequent exacerbations (at least two moderate or one severe hospitalization) despite compliant use of triple inhaled therapy (LAMA + LABA + ICS).
How does ensifentrine (Ohtuvayre) differ from inhaled triple therapy, and how is it taken?
Inhaled triple therapy combines a LAMA, a LABA, and an ICS delivered via a dry-powder or metered-dose inhaler to provide bronchodilation and suppress inflammation. Ensifentrine (Ohtuvayre) represents a different pharmacological class: it is a dual PDE3/4 inhibitor that acts as both a bronchodilator and a non-steroidal anti-inflammatory agent. It is formulated as a liquid suspension administered twice daily (one 3 mg/2.5 mL ampule in the morning and one in the evening) using a standard jet nebulizer. This makes it an option for patients who have poor hand-breath coordination or lack the inspiratory flow required to actuate standard dry-powder or metered-dose inhalers.
Are there other COPD biologics besides dupilumab, and what is mepolizumab's role?
Yes, the biologic options for COPD expanded with the FDA approval of mepolizumab (Nucala) on May 22, 2025. While dupilumab blocks the IL-4/IL-13 receptor alpha to target type 2 inflammation, mepolizumab is a monoclonal antibody that targets interleukin-5 (IL-5), directly inhibiting eosinophil survival and activation. Clinically, mepolizumab is indicated for patients with inadequately controlled COPD and blood eosinophil counts of at least 150 cells/µL, offering a lower initiation threshold than dupilumab's 300 cells/µL restriction. It is administered as a subcutaneous injection once every 4 weeks.
Sources
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). "Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2025 Report." GOLD Guidelines. Published November 2024. Accessed July 2026. https://goldcopd.org/wp-content/uploads/2024/11/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf
- U.S. Food and Drug Administration. Drugs@FDA approval records and labels for Dupixent (BLA 761055 supplement 064, revised 09/2024) and Ohtuvayre (NDA 217389, approved 2024-06-26). CDER database. https://www.accessdata.fda.gov/scripts/cder/daf/
- Bhatt, S. P., et al. "Dupilumab for COPD with Type 2 Inflammation (BOREAS)." New England Journal of Medicine, 2023. https://www.nejm.org/doi/10.1056/NEJMoa2303951
- Bhatt, S. P., et al. "Dupilumab in COPD with Blood Eosinophils >= 300 cells/µL (NOTUS)." New England Journal of Medicine, 2024. https://www.nejm.org/doi/10.1056/NEJMoa2401304
- Anzueto, A., et al. "Ensifentrine, a Dual Phosphodiesterase 3 and 4 Inhibitor, for the Treatment of COPD (ENHANCE-1 and ENHANCE-2)." American Journal of Respiratory and Critical Care Medicine, 2023. https://www.ajmc.com/view/fda-approves-ensifentrine-for-maintenance-treatment-of-adult-patients-with-copd
- Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Files, database update dated July 8, 2026. Medicaid Prescription Drug Pricing Resources. https://www.medicaid.gov/medicaid/prescription-drugs/registration/index.html
- GlaxoSmithKline plc. "GSK Announces FDA Approval of Nucala (mepolizumab) for Chronic Obstructive Pulmonary Disease." GSK Press Release. Published May 22, 2025. Accessed July 2026. https://www.gsk.com/en-gb/media/press-releases/
- Pavord, I. D., et al. "Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (METREX and METREO)." New England Journal of Medicine, 2017. https://www.nejm.org/doi/full/10.1056/NEJMoa1708208
